The effects of vitamin D in polycystic ovarian syndrome
Article Sidebar
Main Article Content
Abstract
The common endocrine disorder in women is that Polycystic ovarian syndrome (PCOS) specially in reproductive age. The study included 60 women suffer from the PCOS attending the obstetrics and gynecology unit in Kirkuk General Hospital, ages ranged from 18 to 42 years old. Also, the study included 30 non PCOS women as a control group. To assess the effect of Vitamin D in women suffering from polycystic ovarian syndrome. Serum Vitamin D was evaluated using Enzyme linked immunosorbent assay (ELISA) technique. The study reported that 58.3% of PCOS women enrolled in this study were within the age group 16- 25 year. The study reported that the BMI of PCOS women was (mean 30.98 ± 4.02) Kg/cm2, whereas (22.77±2.52) Kg/cm2 of the control group (P: 0.0004). A significant difference recorded in the study in the Vitamin D levels in Polycystic overian syndrom women compared to the healthy group (mean 18.69±5.11 25.99±5.70).
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
[1] Bozdag, G.; Mumusoglu, S.; Zengin, D.; Karabulut, E. and Yildiz, B.O.(2016). The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod, 31 (12): 2841–2855.
[2] Begum, S.; Hossain, M. Z.; Rahman, M. F. and Banu, L. A. (2017). Polycystic ovarian syndrome in women with acne. JPAD, 22 (1): 24-29.
[3] Asemi, Z.; Foroozanfard, F.; Hashemi, T.; Bahmani, F.; Jamilian M.; Esmaillzadeh, A. (2015). Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome. Clin Nutr, 34 (4): 586-592.
[4] Minooee, S.; Tehrani, F. R.; Mirmiran, P. and Azizi, F. (2016). Low birth weight may increase body fat mass in adult women with polycystic ovarian syndrome. International Journal of Reproductive BioMedicine, 14 (5): 335.
[5] Goodarzi, M. O.; Dumesic, D. A.; Chazenbalk, G. and Azziz, R. (2011). Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev En, 7 (4): 219– 231.
[6] He, C.; Lin, Z.; Robb, S. W. and Ezeamama A. E. (2015). Serum vitamin D levels and polycystic ovary syndrome: a systematic review and meta-analysis. Nutr, 7 (6): 4555-4577.
[7] Rejnmark, L.; Bislev, L. S.; Cashman, K. D.; Eiríksdottir, G.; Gaksch, M.; Grübler, M. et al. (2017). Non-skeletal health effects of vitamin D supplementation: A systematic review on findings from meta-analyses summarizing trial data. PLoS One, 12 (7): e0180512.
[8] Keshavarz, M. A.; Moradi, S.; Emami, Z. and Rohani, F. (2017). Association between serum 25 (OH) vitamin D and metabolic disturbances in polycystic ovary syndrome. Neth J Med, 1 (5): 191-196.
[9] Bellver, J.; Rodríguez-Tabernero, L.; Robles, A.; Muñoz, E.; Martínez, F.; Landeras, J. et al. (2018). Polycystic ovary syndrome throughout a woman’s life. Journal of assisted reproduction and genetics, 35 (1): 25-39.
[10] Koivunen, R.; Laatikainen, T.; Tomás, C.; Huhtaniemi, I.; Tapanainen, J.; and Martikainen, H. (1999). The prevalence of polycystic ovaries in healthy women. Acta obstetricia et gynecologica Scandinavica, 78 (2): 137-141.
[11] Winters, S. J.; Talbott, E.; Guzick, D.S.; Zborowski, J. and McHugh, K. P. (2000). Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertility and sterility, 73 (4): 724-729.
[12] Johnstone, E. B.; Rosen, M. P.; Neril, R.; Trevithick, D.; Sternfeld, B.; Murphy, R. and Cedars, M. I. (2010). The polycystic ovary post-Rotterdam: acommon, age-dependent finding in ovulatory women without metabolicsignificance Journal of Clinical Endocrinology & Metabolism, 95 (11): 4965-4972.
[13] Jahromi, B.N.; Dabaghmanesh, M.H.; Parsanezhad, M. E. and Fatehpoor, F. (2017). Association of leptin and insulin resistance in PCOS: A case-controlled study. International Journal of Reproductive BioMedicine, 15 (7): 423.
[14] Alnakash, A. H. and Al-Taee, N. K. (2007). Polycystic ovarian syndrome: the correlation between the LH/FSH ratio and disease manifestations. Middle East Fertility Society Journal, 12 (1): 35.
[15] Anderson, A. D.; Solorzano, C. M. B. and McCartney, C. R. (2014). Childhood obesity and its impact on the development of adolescent PCOS. In
Seminars in reproductive medicine, Thieme Medical Publishers, 32 (3): 202-213.
[16] Ollila, M. M.; Piltonen, T.; Puukka, K.; Ruokonen, A.; Järvelin, M. R.; Tapanainen, J. S.; Franks, S. and Morin-Papunen, L. (2016). Weight gain and dyslipidemia in early adult adulthood associate with polycystic ovary syndrome: prospective cohort study. J Clin Endocrinol Metab, 101: 739–747.
[17] Yuan, C.; Liu, X.; Mao, Y.; Diao, F.; Cui, Y., and Liu, J. (2016). Polycystic ovary syndrome patients with high BMI tend to have functional disorders of androgen excess: a prospective study. Journal of biomedical research, 30 (3): 197.
[18] Ozkaya, M.; Cakal, E.; Ustun, Y. and Engin-Ustun, Y. (2010). Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. Fertil Steril, 93: 880-884.
[19] Altinkaya, S. Ö.; Nergiz, S.; Küçük, M. and Yüksel, H. (2014). Apelin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome. European Journal of Obstetrics & Gynecology and Reproductive Biology, 176: 168-172.
[20] Muscogiuri, G.; Altieri, B.; Annweiler, C.; Balercia, G.; Pal, H. B. et al. (2017). Vitamin D and chronic diseases: the current state of the art. Arch toxicol, 91 (1): 97-107.
[21] Ghadimi, R.; Esmaeilzadeh, S.; Firoozpour, M. and Ahmadi, A. (2014). Does vitamin D status correlate with clinical and biochemical features of polycystic ovarysyndrome in high school girls? Caspian J Intern Med, 5: 202-208.
[22] Wehr, E.; Trummer, O.; Giuliani, A.; Gruber, H. J.; Pieber, T. R. and Obermayer-Pietsch, B. (2011). Vitamin D-associated polymorphisms are related to insulin resistance and vitamin D deficiency in polycystic ovary syndrome. Eur J Endocrinol, 164: 741-749.
[23] Panidis, D.; Balaris, C.; Farmakiotis, D.; Rousso, D.; Kourtis, A.; Balaris, V. et al. (2005). Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome. Clinical Chemistry, 51 (9): 1691-1697.
[24] Selimoglu, H.; Duran, C.; Kiyici, S.; Ersoy, C.; Guclu, M.; Ozkaya, G. et al. (2010). The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome. Journal of endocrinological investigation, 33 (4): 234-238.
[25] Mathieu, C. (2015). Vitamin D and diabetes: where do we stand? Diabetes Res Clin Pract, 102: 201-209.
[26] Bhanuprakash, R. G.; Sivaprasad, M., and Shalini, T. (2015). Plasma vitamin D status in type 2 diabetes patients with and 1 without retinopathy. Nutrition, 31: 959-963.
[27] Forouhi, N. G.; Cooper, A.; Boucher, B. J. and Wareham, N. J. (2008). Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990–2000. Diabetes, 57 (10): 2619-2625.
[28] Thomson, R. L.; Spedding, S. and Buckley, J. D. (2012). Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin endocrinol, 77 (3): 343-350.
[29] Krul-Poel, Y. H.; Snackey, C.; Louwers, Y. V.; Lips, P.; Lambalk, C. B.; Laven, J. and Simsek, S. (2013). The role of vitamin D in metabolic disturbances in polycystic ovary syndrome (PCOS): a systematic review. Eur J Endocrinol, 169: 853-865.